Filing Details
- Accession Number:
- 0001209191-19-012998
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-02-25 16:40:26
- Reporting Period:
- 2019-02-21
- Accepted Time:
- 2019-02-25 16:40:26
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1689813 | Biohaven Pharmaceutical Holding Co Ltd. | BHVN | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1226675 | P Julia Gregory | C/O Biohaven Pharmaceuticals, Inc. 215 Church Street New Haven CT 06510 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Shares | Acquisiton | 2019-02-21 | 12,000 | $23.63 | 12,000 | No | 4 | M | Direct | |
| Common Shares | Disposition | 2019-02-21 | 12,000 | $43.56 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Shares | Stock Option (Right to Buy) | Disposition | 2019-02-21 | 12,000 | $0.00 | 12,000 | $23.63 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 24,000 | 2027-08-01 | No | 4 | M | Direct |
Footnotes
- This exercise and the subsequent sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 22, 2019.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.20 - $44.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- This option grant was made pursuant to the Issuer's non-employee director compensation policy. The common shares underlying this option vest in three equal installments on August 2, 2018, 2019 and 2020, subject to the Reporting Person's continuous service with the Issuer at each vesting date.
Billionaire Hedge Funds
